SCHEMBL3698741

SCHEMBL3698741

COc1cnc2[nH]cc(C(=O)c3cccc(N)c3)c2c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AAK1 Q2M2I8 1/20 0.53
KIT P10721 5/20 0.47
NEK1 Q96PY6 1/20 0.45
MTNR1A P48039 1/20 0.45
MTNR1B P49286 1/20 0.45
BTK Q06187 1/20 0.45
AXL P30530 5/20 0.45
NTRK1 P04629 2/20 0.43
DYRK3 O43781 1/20 0.43
ROCK2 O75116 1/20 0.43
PRKD3 O94806 1/20 0.43
MAP4K4 O95819 1/20 0.43
LCK P06239 1/20 0.43
CDK1 P06493 1/20 0.43
FGFR1 P11362 1/20 0.43
RPS6KB1 P23443 1/20 0.43
MARK3 P27448 1/20 0.43
FLT4 P35916 1/20 0.43
FLT3 P36888 1/20 0.43
SYK P43405 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3711724 0.89 AAK1 (0.55) AAK1NEK1MTNR1AMTNR1BBTK
SCHEMBL858562 0.85 KIT (0.66) AAK1KITNEK1AXLNTRK1
SCHEMBL3705033 0.85 AAK1 (0.47) AAK1KITAXLNTRK1DYRK3
SCHEMBL10283344 0.84 AAK1 (0.51) AAK1NEK1MTNR1AMTNR1BBTK
SCHEMBL298453 0.83 AAK1 (0.49) AAK1NEK1MTNR1AMTNR1BAXL
SCHEMBL297306 0.82 BRAF (0.45) AAK1KITAXLNTRK1DYRK3
SCHEMBL297839 0.82 AAK1 (0.45) AAK1KITAXLNTRK1DYRK3
SCHEMBL298022 0.82 PAK1 (0.48) AAK1KITNTRK1MAP4K4LCK
SCHEMBL3700265 0.81 MTNR1A (0.44) AAK1KITMTNR1AMTNR1BAXL
SCHEMBL3507602 0.80 CYP2C9 (0.45) AAK1KITNEK1MTNR1AMTNR1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120122860-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS PLEXXIKON, INC. 2012-05-17 US disclosed
US-20120122860-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS PLEXXIKON, INC. 2012-05-17 US disclosed
US-20120122860-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS PLEXXIKON, INC. 2012-05-17 US disclosed
WO-2010129570-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS PLEXXIKON, INC. (US) 2010-11-11 WO disclosed
WO-2010129570-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS PLEXXIKON, INC. (US) 2010-11-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122860-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS BRAF, RAF1, ARAF AAK1 247/4885KIT 1330/4885NEK1 1228/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.